Evidence map›Paper›PMID 39847771›Full record

ArticleJMIR formative research2025

Usability and Usefulness of a Symptom Management Coaching System for Patients With Cancer Treated With Immune Checkpoint Inhibitors: Comparative Mixed Methods Study.

Savannah Lucia Caterina Glaser, Itske Fraterman, Noah van Brummelen, Valentina Tibollo, Laura Maria Del Campo, Henk Mallo, Sofie Wilgenhof, Szymon Wilk, Vitali Gisko, Vadzim Khadakou and 3 more

Abstract readComparative Study
In one paragraph

Article in JMIR formative research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Savannah Lucia Caterina GlaserDepartment of Medical Informatics, Amsterdam UMC - University of Amsterdam, Amsterdam, Netherlands.ORCID 0000-0003-0103-079X
Itske FratermanDepartment of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, Netherlands.ORCID 0000-0001-7974-8422
Noah van BrummelenDepartment of Medical Informatics, Amsterdam UMC - University of Amsterdam, Amsterdam, Netherlands.ORCID 0009-0005-8719-7882
Valentina TibolloLaboratory of Informatics and Systems Engineering for Clinical Research, Istituti Clinici Scientifici Maugeri SpA SB IRCCS, Pavia, Italy.ORCID 0000-0003-2687-3822
Laura Maria Del CampoAssociazione Italiana Malati di Cancro, Rome, Italy.ORCID 0000-0002-9882-300X
Henk MalloDepartment of Medical Oncology, Antoni van Leeuwenhoek, Amsterdam, Netherlands.ORCID 0000-0001-6555-4942
Sofie WilgenhofDepartment of Medical Oncology, Antoni van Leeuwenhoek, Amsterdam, Netherlands.ORCID 0000-0002-3309-4555
Szymon WilkInstitute of Computing Science, Poznan University of Technology, Poznan, Poland.ORCID 0000-0002-7807-454X
Vitali GiskoBITSENS JSC, Vilnius, Lithuania.ORCID 0009-0009-3886-7228
Vadzim KhadakouBITSENS JSC, Vilnius, Lithuania.ORCID 0009-0007-3350-6269
Ronald CornetDepartment of Medical Informatics, Amsterdam UMC - University of Amsterdam, Amsterdam, Netherlands.ORCID 0000-0002-1704-5980
Manuel OttavianoLife Supporting Technologies, Universidad Politécnica de Madrid, Madrid, Spain.ORCID 0000-0003-0002-4988
Stephanie MedlockDepartment of Medical Informatics, Amsterdam UMC - University of Amsterdam, Amsterdam, Netherlands.ORCID 0000-0002-2679-8095

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe prognosis for patients with several types of cancer has substantially improved following the introduction of immune checkpoint inhibitors, a novel type of immunotherapy. However, patients may experience symptoms both from the cancer itself and from the medication. A prototype of the eHealth tool Cancer Patients Better Life Experience (CAPABLE) was developed to facilitate symptom management, aimed at patients with melanoma and renal cell carcinoma treated with immunotherapy. Better usability of such eHealth tools can lead to improved user well-being and reduced risk of harm. It is unknown for usability evaluations whether certain usability problems would only be evident to patients whose condition closely resembles the target population, or if a broader group of patients would lead to the identification of a broader range of potential usability issues.

objectiveThis study aims to evaluate the CAPABLE prototype by conducting tests to assess usability, user experience, and perceived acceptability among end users, and to assess any agreements or differences in the results of our wide range of participants.

methodsThis usability study was executed by interviewing participants with a melanoma or renal cell carcinoma diagnosis who have received immunotherapy and participants without direct experience with the targeted cancer types who have not received immunotherapy. Participants were asked to review the concept of the tool, perform think-aloud tasks, and complete the System Usability Scale and a Perceived Usefulness questionnaire. Usability problems were extracted from the interview data by independent coding and mapped to an eHealth Usability Problem Framework.

resultsWe included 21 participants in the study, aged 29 to 73 years; 13 participants who had received immunotherapy and 8 participants who had not received immunotherapy. In total, 76 usability problems were identified. A total of 22 usability problems were in the task-technology fit category of the usability framework, mostly regarding the coaching and symptom functionality of the prototype. Critical problems regarding the symptom monitoring functionality were mainly found by participants who had received immunotherapy. For 8 out of 10 statements in the Perceived Usefulness questionnaire, more than 75% of participants agreed or strongly agreed. The overall mean System Usability Scale score was 80 out of 100 (SD 11.3).

conclusionsDespite identified usability issues, participants responded positively to the Perceived Usefulness questionnaire regarding the evaluated tool. Further analysis of the usability problems indicates that it was essential to include participants who matched the target end users. Participants treated with immunotherapy, specifically with previous experience in immune-related adverse events, encountered critical problems with symptom reporting that would not have been identified if these participants were not included. For other tasks and functionalities, it seems likely that loosening the inclusion criteria would have resulted in sufficient feedback without critical missing usability issues.

Indexed as

Carcinoma, Renal CellImmune Checkpoint InhibitorsKidney NeoplasmsMelanomaMentoringNeoplasmsAdultAgedFemaleHumansMaleMiddle AgedSurveys and QuestionnairesTelemedicineImmune Checkpoint Inhibitorsacceptabilitycancer treatmentcaregiverscoaching systemcomparative qualitative studyeHealth applicationsimmune checkpoint inhibitorsimmunotherapymedicationmelanomaoncologypatient educationpatients with cancerrenal cell carcinomasymptom managementusabilityusefulnesswell-being interventions

Identifiers

PMID39847771
PMCPMC11803325

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.